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Effect of lactate administration on brain
lactate levels during hypoglycemia in
patients with type 1 diabetes
Evita C Wiegers1,*, Hanne M Rooijackers2,*, Cees J Tack2,
Bart WJ Philips1, Arend Heerschap1,
Marinette van der Graaf1,3,* and Bastiaan E de Galan2,*
Abstract
Administration of lactate during hypoglycemia suppresses symptoms and counterregulatory responses, as seen in
patients with type 1 diabetes and impaired awareness of hypoglycemia (IAH), presumably because lactate can substitute
for glucose as a brain fuel. Here, we examined whether lactate administration, in a dose sufficient to impair awareness of
hypoglycemia, affects brain lactate levels in patients with normal awareness of hypoglycemia (NAH). Patients with NAH
(n¼ 6) underwent two euglycemic-hypoglycemic clamps (2.8mmol/L), once with sodium lactate infusion (NAH wjlac)
and once with saline infusion (NAH wjplacebo). Results were compared to those obtained during lactate administration
in patients with IAH (n¼ 7) (IAH wjlac). Brain lactate levels were determined continuously with J-difference editing 1H-
MRS. During lactate infusion, symptom and adrenaline responses to hypoglycemia were considerably suppressed in NAH.
Infusion of lactate increased brain lactate levels modestly, but comparably, in both groups (mean increase in NAH wjlac:
0.12 0.05mmol/g and in IAH wjlac: 0.06 0.04 mmol/g). The modest increase in brain lactate may suggest that the
excess of lactate is immediately metabolized by the brain, which in turn may explain the suppressive effects of lactate on
awareness of hypoglycemia observed in patients with NAH.
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Introduction
Hypoglycemia is the most frequent side-effect of insulin
therapy in patients with type 1 diabetes. When blood
glucose levels drop, this normally initiates a hierarchic-
ally organized counterregulatory response, which
includes release of counterregulatory hormones and
the appearance of hypoglycemic symptoms. It has
been demonstrated that the administration of lactate
considerably diminishes symptomatic and hormonal
responses to hypoglycemia and simultaneously miti-
gates cognitive dysfunction during hypoglycemia.1–3
These effects are suggested to be the result of lactate
acting as an alternative fuel for the brain, when glucose
supply is low.2 Clinically, the administration of lactate
mimics the situation seen in patients with type 1 dia-
betes and impaired awareness of hypoglycemia (IAH).
In IAH, the threshold for the onset of hypoglycemic
symptoms and counterregulatory hormone responses
is shifted to lower glucose values, which substantially
increases the risk for severe hypoglycemia.4
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Most studies that investigated the effects of lactate
administration during hypoglycemia have focused on
clinical effects (i.e. symptoms, hormonal responses
and cognitive function), and did not examine physio-
logical changes in the brain. Whether elevated plasma
lactate levels lead to an accumulation of lactate in the
brain is subject of debate. In a 13C-MR study, per-
formed under euglycemic conditions in non-diabetic
subjects, it was calculated that brain lactate levels and
lactate oxidation increase almost linearly with the
increase in plasma lactate levels.5 In contrast, other
studies have reported direct oxidation of lactate after
its transport across the blood–brain barrier, with lim-
ited accumulation in the brain.6,7 Thus, lactate oxida-
tion may even spare glucose as a cerebral fuel under
euglycemic conditions.8
The only study that has investigated the effect of
exogenous lactate on human brain lactate concentra-
tions during hypoglycemia, calculated increased brain
lactate concentrations without increased oxidation, in
patients with type 1 diabetes compared to healthy vol-
unteers.9 Such elevated brain lactate levels are in line
with studies that demonstrated an enhanced capacity to
transport lactate into the brain in patients with diabetes
and IAH.10,11 The lack of a euglycemic control and a
placebo arm (i.e. no lactate infusion) precluded conclu-
sions about lactate accumulation during euglycemia
versus hypoglycemia, or about the effect of lactate infu-
sion on awareness of hypoglycemia.
In the current study, we aimed to show that infusion
of lactate, in a dose sufficient to impair awareness of
hypoglycemia in patients with type 1 diabetes and
normal awareness of hypoglycemia (NAH), increases
brain lactate levels. Secondly, we aimed to compare
the effect of lactate administration on brain lactate
levels during euglycemia and hypoglycemia between
patients with NAH and those with IAH.
Material and methods
Participants
We enrolled seven patients with type 1 diabetes and
NAH and seven patients with type 1 diabetes and
IAH. The classification of awareness state was based
on the Dutch modified version of the Cox question-
naire.12,13 Patients with type 1 diabetes were eligible if
they were younger than 50 years, had an HbA1c below
9.0% (75mmol/mol) and were free from microvascular
complications, except for background retinopathy.
Exclusion criteria included contraindications to the
MRI examination, a history of brain injury, epilepsy,
liver or cardiovascular diseases, anxiety disorders, and
the use of drugs other than insulin interfering with glu-
cose metabolism. One participant with NAH moved
too much during data acquisition, which hampered
MR data quality and was consequently excluded from
data analysis. The study was approved by and per-
formed in accordance with the ethical standards of
the institutional review board of the Radboud univer-
sity medical center (Commissie Mensgebonden
Onderzoek Arnhem-Nijmegen) and with the Helsinki
declaration of 1975/1983. All participants gave written
informed consent.
Study protocol
Patients with NAH underwent two hyperinsulinemic
euglycemic-hypoglycemic clamp studies, once with
sodium lactate infusion (NAH wjlac) and once with
saline infusion (NAH wjplacebo), as described below.
Experiments were carried out in a single-blind fashion
(i.e. participants were blinded for the infusions) and in
randomized order, scheduled at least two weeks apart.
In female participants, both experiments were per-
formed during equal phases of the menstrual cycle.
Patient with IAH participated only in the sodium lac-
tate infusion study arm (IAH wjlac).
Participants came to the research facility in the
morning after an overnight fast, having abstained
from smoking, alcohol and caffeine containing sub-
stances for 24 h prior to the experiment, and from
strenuous exercise for at least two days before the
experiment. In addition, participants were instructed
to prevent hypoglycemia and to check their blood glu-
cose levels regularly in the 24 h before the experiment.
The brachial artery of the non-dominant arm was
cannulated under local anesthesia (Xylocaine 2%) for
frequent blood sampling. Blood was sampled every
5min for the determination of plasma glucose and
plasma lactate levels (Biosen C-line; EKF
Diagnostics). An intravenous catheter was inserted in
the antecubital vein of the contralateral arm for infu-
sion of glucose 20% (Baxter B.V., Deerfield, IL), insu-
lin (insulin aspart; Novo Nordisk, Bagsvaerd,
Denmark) and sodium lactate (600mmol/L; Spruyt
Hillen, Ijsselstijn, The Netherlands and prepared by
the Department of Pharmacy, Radboud university
medical center, Nijmegen, The Netherlands) or
normal saline (sodium chloride; 0.9%).
After cannulations, a two-step hyperinsulinemic
(60 mU/m2/min) euglycemic (5.0mmol/L)-hypoglycemic
(2.8mmol/L) glucose clamp was initiated, and partici-
pants were placed in the MR scanner for baseline MR
spectroscopy (MRS) data acquisition. At 15min after
the start of the euglycemic clamp, infusion of sodium
lactate, or an equivalent volume of saline, was started,
while MRS data acquisition continued. We aimed for
plasma lactate levels of approximately 3.5mmol/L and
initially used a primed (50mmol/kg/min for 15min)
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continuous (30mmol/kg/min) infusion of sodium lactate.
Since achieved plasma lactate levels were slightly above
target levels, the dose was lowered after the first two par-
ticipants (both patients with NAH) to 40mmol/kg/min
for 15min and 25mmol/kg/min for the remainder of the
experiment. After 25min, blood glucose levels were
allowed to drop to 2.8mmol/L and were maintained at
that level for 45min. Hypoglycemic symptoms were
quantified with a validated questionnaire just prior to
positioning the participant in the MR scanner and at
the end of the stable hypoglycemic phase. Participants
were asked to score from 0 to 6 (none to most severe)
for each of 18 symptoms which included six autonomic
symptoms, six neuroglycopenic symptoms, four general
and two dummy symptoms. Additional blood samples
were taken for determination of plasma insulin, pH, cat-
echolamines, cortisol and growth hormone prior to the
start of the sodium lactate or saline infusion (baseline),
at the end of the euglycemic phase and at the end
of the hypoglycemic phase. During hypoglycemia, coun-
terregulatory hormone responses were determined at
15-min intervals (see Figure 1(a) for a schematic overview
of the study protocol). After completing both experimen-
tal days, patients with NAH were asked on which
day the hypoglycemic phase was most evident or felt
more intense.
MRS protocol and data analysis
To measure brain lactate, we performed MR spectros-
copy (MRS) on a 3T MR system (MAGNETOM
Prisma, Siemens, Erlangen) using a body coil for exci-
tation and a 12-channel receive-only head coil. A T1-
weighted anatomical image (MPRAGE, echo time (TE)
2.4ms, repetition time (TR) 1900ms, and a field of view
of 256 256 mm2) was acquired, and a 22.5 cm3 voxel
for MRS data acquisition was placed in the periven-
tricular and supraventricular region (Figure 2(a)).
Brain lactate levels were then determined continuously
with an interleaved J-difference editing semi-LASER14
spectroscopy sequence (TE 144 ms, TR 3000ms and 8
averages). J-difference editing was performed with fre-
quency selective inversion MEGA pulses15 (30ms,
75Hz bandwidth). Unsuppressed water spectra (TE
33ms, TR 5000ms and 8 averages) were acquired
from the same voxel for signal quantification.
Additionally, at the end of euglycemia and at the end
of hypoglycemia, we acquired MR spectra without J-
difference editing from the same voxel (sLASER, TE
33ms, TR 3000ms, 32 averages) to explore differences
in other major brain metabolites.
The J-difference edited spectra were zerofilled from
1024 to 2048 data points and phase and frequency
aligned.16 Motion-corrupted spectra, identified as a
spectrum which deviated more than 2.6 standard
deviations from the average spectrum of that partici-
pant,17 were discarded. Subsequently, spectra were sub-
tracted pairwise. The difference spectra were averaged
within participants across six different phases: baseline
(i.e. before the start of lactate or placebo infusion),
euglycemia, transition to hypoglycemia, and each 15-
min block of hypoglycemia. From these final difference
spectra, the cerebral lactate doublet at 1.3 ppm was
quantified using the AMARES algorithm in
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Figure 1. Study protocol, plasma glucose and plasma lactate
levels. (a) Schematic overview of the study protocol. MRS
measurements were performed continuously during euglycemia
and hypoglycemia. Counterregulatory hormone responses (CH)
and hypoglycemic symptoms (Symp) were determined at several
time points during euglycemia and hypoglycemia, as indicated. (b)
Time courses of plasma glucose and (c) plasma lactate levels. The
dashed lines represent the start of the lactate or saline infusion
(T¼ 0min), the end of euglycemia, and the start of hypoglycemia.
Open circles: patients with type 1 diabetes and NAH with saline
infusion (NAH wjplacebo); black circles: patients with type 1
diabetes and NAH with lactate infusion (NAH wjlac); black tri-
angles: patients with type 1 diabetes and IAH with lactate infusion
(IAH wjlac).
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jMRUI.18 Visual inspection of the difference spectra
showed co-edited macromolecules at 1.2 ppm, which
were included in the fitting routine in AMARES to
avoid overestimation of the lactate signal.19 The unsup-
pressed water signal was used as an internal standard
for absolute quantification and we took the voxel com-
position and contribution of plasma lactate into
account.20 We assumed a T2 of 240ms for cerebral lac-
tate,21 and a T2 of 80ms and 110ms for water in gray
and white matter, respectively.22 The voxel composition
(i.e. percentages white matter, grey matter and cerebro-
spinal fluid) was determined by segmenting the T1-
weighted anatomical images using SPM8 (Wellcome
Trust Centre for Neuroimaging, UCL, London, UK)
and subsequently co-registering the segmented image
with the MRS voxel location. As the voxel mainly con-
tained white matter, we assumed a vessel volume of
2%.23,24
Spectra acquired without J-difference editing were
analyzed using the LCModel software.25 A basis set
was created in Bruker TopSpin, and extended with a
measured macromolecular baseline. Metabolites quan-
tified with Crame´r-Rao lower bounds >50% were not
included in the analysis (as recommended by the
LCModel manual26). The unsuppressed water signal
was used as a reference for absolute quantification of
aspartate (Asp), total choline (tCho), total creatine
(tCre), glutamate (Glu), glutamine (Gln), myo-inositol
(mI), total N-acetylaspartate (tNAA), scyllo-inositol
(scyllo) and taurine (Tau).
Analytical methods
Plasma insulin was determined by an in-house radio-
immunoassay (RIA).27 Plasma adrenaline and
noradrenaline were analyzed by high-performance
liquid chromatography combined with fluorometric
detection.28 Plasma growth hormone and cortisol
were determined using a routine analysis method with
an electrochemiluminescent immunoassay on a
Modular Analytics E170 (Roche Diagnostics GmbH,
Mannheim, Germany). pH was measured by routine
arterial blood gas analysis on the RapidPoint 500
(Siemens Nederland B.V., Den Haag, the Netherlands).
Statistical analysis
Differences in means or medians within the NAH group
(NAH wjlac vs. NAH wjplacebo) and differences within
groups between euglycemia and hypoglycemia were
statistically tested with paired Student t tests or
Wilcoxon signed rank tests when data were not nor-
mally distributed. Differences between NAH wjlac
and IAH wjlac were compared with two-sided
Student t tests or Mann–Whitney U tests, when appro-
priate. Serial data were compared between NAH wjlac
and NAH wjplacebo with a two-way repeated measure
ANOVA. To analyze effects over time in patients with
IAH, a one-way repeated measure ANOVA was per-
formed. Since patients with IAH were only studied with
lactate infusion, comparison to a placebo condition is
not possible. Thus, to determine whether there was
an effect of lactate infusion on brain lactate levels in
patients with IAH, the area under the curve (AUC) of
the baseline-corrected brain lactate levels was calcu-
lated by trapezoidal numerical integration, and a one-
sample t test was performed. Differences in means at
baseline across the three groups were analyzed by one-
way ANOVA followed by pairwise Bonferroni post hoc
tests. All data are expressed as meanSD unless
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Figure 2. Example of difference spectra. (a) Typical location of the MRS voxel on a T1-weighted anatomical image. (b) Representative
examples of difference spectra of one subject NAH (NAH wjplacebo and NAH wjlac) and one subject with IAH (IAH wjlac). The
baseline difference spectra were recorded before the start of lactate or placebo infusion. Lac: lactate; MM: macromolecules.
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otherwise indicated. Significance levels of Student t
tests were not corrected for multiple testing. A P
value <0.05 was considered statistically significant.
Statistical analyses were performed with IBM SPSS
Statistics 20.
Results
Participants were well-matched for relevant clinical
parameters, including age, duration of diabetes and gly-
cemic control (Table 1). Upon arrival at the research
facility, plasma glucose levels were slightly elevated
with no significant differences between groups
(9.4 3.4, 7.4 1.7 and 10.3 4.9mmol/L in NAH
wjlac, NAH wjplacebo and IAH wjlac, respectively).
Stable euglycemia was achieved at a glucose level of
5.1 0.2mmol/L and stable hypoglycemia at
2.8 0.1mmol/L, again with no differences between
groups or intervention (Figure 1(b)). Plasma insulin
levels during the clamp were similar for all groups
and conditions (data not shown). Plasma lactate levels
increased similarly in NAH wjlac and IAH wjlac by
3.5-fold to 3.6 0.5mmol/L within 15min after
starting the lactate infusion, and remained at that
level for the remainder of the experiment (Figure
1(c)). During the control experiment, i.e. when saline
was infused, plasma lactate levels did not change sig-
nificantly from baseline levels in NAH wjplacebo
(p¼ 0.58). Sodium lactate infusion caused the pH to
increase in both groups to similar extent (from
7.41 0.02 at baseline to 7.48 0.01 at the end of hypo-
glycemia, p< 0.001), whereas saline infusion did not
affect the pH (7.40 0.02 versus 7.42 0.03). Glucose
infusion rates (GIRs) during hypoglycemia
(Supplementary Figure 1) were not significantly differ-
ent across groups and intervention (mean GIR:
3.1 1.3, 2.7 1.0 and 3.3 1.3mg/kg/min for NAH
wjlac, NAH wjplacebo and IAH wjlac, respectively).
Hypoglycemic symptoms and counterregulatory
hormones
Lactate infusion clearly suppressed total symptom
scores during hypoglycemia in patients with NAH, as
compared to placebo (p¼ 0.03, Figure 3), and
resembled symptom score of patients with IAH when
lactate was infused (p¼ 0.18 between groups).
Symptom subcategories are depicted in Table 2. Five
out of six patients with NAH indicated that hypogly-
cemia was less severe on the day of the lactate infusion,
one patient experienced no difference between both
study days. In patients with IAH, neither the total
nor the subcategory symptom score changed signifi-
cantly in response to hypoglycemia. Lactate infusion
considerably suppressed the adrenaline response to
hypoglycemia in patients with NAH as compared to
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Figure 3. Difference in symptom scores. Total symptoms
scores in response to hypoglycemia in patients with type 1
diabetes and NAH with saline infusion (NAH wjplacebo), patients
with NAH with lactate infusion (NAH wjlac) and patients with
IAH with lactate infusion (IAH wjlac). *p< 0.05 **p< 0.01.
Table 1. Participant characteristics.
T1DM NAH T1DM IAH
Age (yrs) 28.0 10.3 25.9 6.0
Gender (M/F) 3/3 3/4
BMI (kg/m2) 24.0 2.5 24.0 2.1
Duration of T1DM (yrs) 11.6 5.9 13.2 5.8
HbA1c (mmol/mol [%]) 54.7 9.1
[7.2 0.8]
55.0 5.0
[7.2 0.5]
Self reported exercise
(hours/week)
3.5 0.9 2.9 1.5
Note: Data are presented as number or mean SD. M: male; F: female;
BMI: body mass index; T1DM NAH: type 1 diabetes with normal aware-
ness of hypoglycemia; T1DM IAH: type 1 diabetes with impaired aware-
ness of hypoglycemia.
Table 2. Hypoglycemia-induced changes in symptom subscores
(median [interquartile range]).
T1DM NAH T1DM IAH
Placebo
infusion
Lactate
infusion
Lactate
infusion
Autonomic 7.5 [2.5; 15.5]# 2.5 [0.5; 4.5] 1 [2; 3]
Neuroglycopenic 3.5 [0.75; 7]# 2 [0.25; 3.5] 2 [1; 2]
General 3.5 [3; 4.75]*,# 2 [0.75; 3.25]# 0 [1; 1]
*p< 0.05 vs. NAH wjlacp< 0.05 vs. euglycemia. T1DM NAH: type 1
diabetes with normal awareness of hypoglycemia; T1DM IAH: type 1
diabetes with impaired awareness of hypoglycemia.
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placebo infusion (p< 0.01; Figure 4). Lactate infusion
also suppressed cortisol and hGH responses to hypo-
glycemia in patients with NAH (both p< 0.01), but did
not significantly reduce noradrenaline responses
(p¼ 0.18) (Supplementary Figure 2).
Brain lactate
The tissue content of the MRS voxels was not different
between groups and contained on average 64.1 11.1%
white matter, 32.8 10.5% grey matter and 3.2 1.6%
cerebrospinal fluid. Baseline brain lactate levels
(i.e. before the infusion of lactate or placebo) were
similar across groups (0.58 0.08, 0.64 0.1 and
0.59 0.05 mmol/g in NAH wjlac, NAH wjplacebo
and IAH wjlac, respectively; p¼ 0.42). J-edited differ-
ence MR spectra, recorded during infusion of lactate,
showed an increase of the lactate signal in the brain
(Figure 2(b)). In patients with NAH, brain lactate
levels were higher after infusion of lactate than after
infusing saline (Figure 5(a); mean difference:
0.12 0.05 mmol/g, equivalent to an increase of
20.7 6.6%; p¼ 0.048). There was no significant inter-
action effect (time x infusion) or main effect of time.
Although brain lactate levels in NAH wjlac tended to
be elevated compared to placebo values at each time
point, post hoc analysis revealed that the difference in
brain lactate levels reached significance during the final
30min of the experiment.
In patients with IAH, lactate infusion resulted in an
increase in brain lactate levels compared to baseline
values (Figure 5(b); mean increase: 0.06 0.04 mmol/g,
equivalent to an increase of 10.2 4.2%; AUC of base-
line-corrected brain lactate levels: 4.4 4.3 mmolmin/g;
p¼ 0.03). In these patients, brain lactate levels showed
a trend towards an increase at each time point com-
pared to baseline values, but the trend was stronger
at the beginning of lactate infusion and disappeared
at the end of hypoglycemia. When comparing brain
lactate time curves with lactate infusion between
patients with IAH and NAH, the increase in brain lac-
tate levels in IAH wjlac seemed less pronounced com-
pared to NAH wjlac, but this difference was not
statistically significant (p¼ 0.36). Brain lactate levels
did not change in patients with NAH in response to
hypoglycemia when saline was infused. Notably, there
was no correlation, whatsoever, between brain lactate
levels and plasma lactate levels (R2¼ 0.01, p¼ 0.27).
Other brain metabolites
Brain glutamate levels decreased in response to hypo-
glycemia in patients with NAH, both during lactate
infusion (from 7.5 0.7 to 7.1 1.0 mmol/g, p¼ 0.03)
and while infusing placebo (from 7.6 0.6 to
7.0 0.8 mmol/g, p¼ 0.01). In contrast, hypoglycemia
did not change brain glutamate levels in patients with
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Figure 5. Brain lactate levels. Mean (SEM) baseline corrected and percentage change in brain lactate levels in (a) patients with type
1 diabetes and NAH (NAH wjplacebo and NAH wjlac) and (b) patients with type 1 diabetes and IAH (IAH wjlac). The dashed line
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Figure 4. Adrenaline responses. Adrenaline levels were deter-
mined at baseline (Bsln; i.e. before the infusion of lactate or
saline), during euglycemia (Eu) and at 15-min intervals during
hypoglycemia. Open circles: patients with type 1 diabetes and
NAH with saline infusion (NAH wjplacebo); black circles:
patients with type 1 diabetes and NAH with lactate infusion
(NAH wjlac); black triangles: patients with type 1 diabetes and
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IAH (8.0 0.7 versus 7.8 0.9mmol/g, p¼ 0.59).
Additionally, we found an increase in myo-inositol in
IAH wjlac and a slight decrease in myo-inositol in
NAH wjlac. None of the other major brain metabolites
(Asp, tCho, tCre, Gln, tNAA, scyollo and Tau) was
significantly altered by the hypoglycemic condition in
any of the groups (Supplementary Figure 3).
Discussion
The results of the present study confirm that lactate
infusion considerably suppresses counterregulatory
hormone responses to and symptomatic awareness of
hypoglycemia in patients with NAH. While lactate
infusion did increase brain lactate content, the increase
was modest and not clearly different between patients
with NAH and IAH. The lack of pronounced brain
lactate accumulation suggests that the excess of lactate
is immediately oxidized by the brain which may explain
the suppressive effects of lactate on awareness of hypo-
glycemia in patients with NAH.
Our results are in line with those of several other
studies reporting that elevated plasma lactate levels
result in an increase in cerebral lactate transport and
oxidation, preventing substantial accumulation of brain
lactate upon infusion.6–8 However, an earlier study
reported fivefold higher brain lactate concentrations in
the brain of patients with type 1 diabetes who were
exposed to frequent hypoglycemia, as compared to
healthy controls, when 13C-labelled lactate was adminis-
tered during hypoglycemia.9 Another 13C study that
used the similar methodology in healthy volunteers,
found a linear correlation between plasma and brain
lactate concentrations during euglycemia.5 According
to these calculations, brain lactate levels should have
been as high as 2mmol/g rather than 0.7mmol/g
with the plasma lactate levels of 3.5mmol/L that we
achieved. It should be noted that with 13C-MRS brain,
lactate levels are calculated rather indirectly. These cal-
culations require a number of critical assumptions,
which may result in an overestimation of brain lactate
levels. Here we used 1H-MRS to measure the signal
intensity of brain lactate, which is directly proportional
to the tissue concentration of lactate, thus providing a
direct measurement of brain lactate levels.
Lactate is taken up by the brain through proton-
linked facilitated diffusion by monocarboxylate
transporters (MCTs), and its uptake is driven by a
concentration gradient from blood to brain and further
enhanced by neuronal activation.29,30 Therefore, it is
likely that elevated plasma lactate levels result in an
increased uptake of lactate by the brain. Furthermore,
it has repeatedly been shown that lactate can serve as a
metabolic substrate for the brain,5,7–9,31 especially when
plasma lactate levels are elevated.7,32,33 Lactate taken
up by the brain needs to be converted to pyruvate
before it enters the citric acid cycle, a process catalyzed
by lactate dehydrogenase (LDH). Even relatively small
increases in local brain lactate concentration can drive
lactate utilization by shifting the LDH reaction to pyru-
vate formation and to subsequent oxidation.34 As we
found only a small increase in brain lactate levels, we
posit that lactate taken up by the brain is largely oxi-
dized, both during euglycemia and hypoglycemia.
Increased brain lactate concentrations during hypogly-
cemia are likely responsible for the suppressive effects
on counterregulatory responses in patients with NAH,
presumably because of increased brain lactate oxida-
tion. Alternatively, lactate may exert its suppressive
effects via alterations in cerebral blood flow, redox sig-
naling or neuronal activity.35,36
Since brain lactate transport capacity is reported to
be upregulated in patients with IAH,10,11 one can
expect higher brain lactate levels in patients with IAH
than in patients with NAH. Brain lactate concentra-
tions are the result of a balance between its uptake,
production, oxidation and export. The absence of a
difference in brain lactate concentrations between
NAH wjlac and IAH wjlac at the currently elevated
plasma lactate levels either indicates comparable brain
lactate uptake in both groups, or upregulation of both
lactate uptake and lactate oxidation in patients with
IAH. Without the use of exogenous lactate infusion,
we previously showed that brain lactate levels fall in
response to hypoglycemia in patients with IAH, but
not in those with NAH.37 This may indeed indicate
upregulated capacity to oxidize lactate in patients
with IAH. Analogously, the trend towards increased
brain lactate levels in the current study disappeared at
the end of hypoglycemia in patients with IAH, again
hinting at upregulated capacity to oxidize lactate.
When we used intense exercise to raise endogenous
plasma lactate to much higher levels, we observed
higher brain lactate levels in patients with IAH than
in those with NAH.38 Cerebral lactate uptake is not
only dependent on plasma lactate concentrations
but also on pH levels in plasma and in brain.30
The lactate-induced increase in plasma pH value (i.e.
a decrease in Hþ concentration) observed in the current
study may have limited brain lactate uptake in com-
parison to an exercise-induced decrease in plasma pH.
However, these effects are generally small when pH
values remain within the physiological range.
We found brain glutamate levels to fall in response
to hypoglycemia in patients with NAH, which is in line
with previous observations39 and has been attributed to
glutamate oxidation.39–41 This decrease in brain glu-
tamate was also present in patients with NAH when
lactate was infused, which suppressed adrenaline
responses to hypoglycemia. This is in line with the
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absence of a relation between the hypoglycemia-
induced decrease in glutamate and the adrenaline
response to hypoglycemia, as reported by Terpstra
et al.,39 and may indicate that even though lactate is
abundantly available, it is not sufficient to compensate
for the decrease in glucose supply to the brain in
patients with NAH, or alternatively, that lactate oxida-
tion is already saturated in these patients. In contrast,
but again in line with previous data without lactate
infusion,39 brain glutamate did not decrease in patients
with IAH, possibly because of their greater capacity to
use (the excess of) lactate, thus eliminating the need to
oxidize glutamate.
Our study has a small sample size, though based on
power calculations. However, the study population was
homogenous in terms of age, HbA1c and diabetes dur-
ation, and plasma glucose and lactate levels during the
clamps were stable and almost identical in all groups.
The homogeneity of the study population enables effi-
cient comparison, but on the other hand, may limit the
generalisability of the results. Importantly, to quantify
the cerebral lactate content, we took the contribution of
plasma lactate (ranging from 0.8mmol/L to
3.5mmol/L) to the MR signal of brain lactate into
account. Since the voxel consisted of mainly white
matter, we estimated a 2% vessel volume, based on
literature.23,24 Deviations from this estimation (within
the physiological range) may affect the magnitude of
the outcome, but will not affect the main conclusion
of the study.
In conclusion, we show that intravenous lactate
administration reduces awareness of hypoglycemia
and translates into a small increase in brain lactate
levels, with no differences between patients with NAH
and IAH. The rather limited increase in brain lactate
suggests that the excess of lactate is immediately used
by the brain both under euglycemic and hypoglycemic
conditions. An increase in brain lactate oxidation
during hypoglycemia may explain the suppressive
effects of lactate on awareness of hypoglycemia
observed in patients with NAH.
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